C4 Therapeutics (CCCC) Stock Forecast & Price Target

Compare

516 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CCCC Analyst Ratings

Moderate Buy

2 Buy

0 Hold

0 Sell

Based on 2 analysts giving stock ratings to

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CCCC Stock 12 Month Forecast

Average Price Target

$7.50

▲(180.90% Upside)

Based on 2 Wall Street analysts offering 12 month price targets for C4 Therapeutics in the last 3 months. The average price target is $7.50 with a high forecast of $8.00 and a low forecast of $7.00. The average price target represents a 180.90% change from the last price of $2.67.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","2.25":"$2.25","4.5":"$4.5","6.75":"$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.51,2.9323076923076923,3.3546153846153843,3.776923076923077,4.199230769230769,4.621538461538462,5.043846153846154,5.466153846153846,5.888461538461538,6.310769230769231,6.733076923076923,7.155384615384615,7.577692307692308,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.51,2.8938461538461535,3.2776923076923072,3.6615384615384614,4.045384615384615,4.429230769230768,4.813076923076923,5.196923076923077,5.5807692307692305,5.964615384615384,6.348461538461538,6.732307692307692,7.116153846153846,{"y":7.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.51,2.855384615384615,3.2007692307692306,3.546153846153846,3.8915384615384614,4.236923076923077,4.582307692307692,4.927692307692308,5.273076923076923,5.618461538461538,5.963846153846154,6.309230769230769,6.654615384615385,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.61,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$8.00

Average Price Target$7.50

Lowest Price Target$7.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Bradley Canino

Guggenheim

Buy

199.63%

Upside

Initiated

09/03/25

C4 Therapeutics initiated with a Buy at GuggenheimC4 Therapeutics initiated with a Buy at Guggenheim

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

Buy

162.17%

Upside

Reiterated

08/11/25

Evercore ISI Sticks to Their Buy Rating for C4 Therapeutics (CCCC)Earnings Overload SMID Biotech Week in Review

Unknown Analyst

UBS

Not Ranked

UBS

$4→$3.5

Hold

31.09%

Upside

Reiterated

03/03/25

C4 Therapeutics (CCCC) PT Lowered to $3.50 at UBSUBS analyst Colin Bristow lowered the price target on C4 Therapeutics (NASDAQ: CCCC) to $3.50 (from $4.00) while maintaining a Neutral rating.

Etzer Darout

BMO Capital

$20

Buy

649.06%

Upside

Reiterated

02/27/25

C4 Therapeutics: Promising Clinical Developments and Strategic Plans Justify Buy Rating

Derek Archila

Wells Fargo

$12

Buy

349.44%

Upside

Reiterated

02/27/25

Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A) and C4 Therapeutics (NASDAQ: CCCC)We rate shares Overweight as we believe they don't price in enough value for cemsidomide and mgmt's ability to partner that asset.

Leah R. Cann

Brookline Capital Markets

$39→$50

Buy

1772.66%

Upside

Reiterated

01/06/25

C4 Therapeutics price target raised to $50 from $39 at BrooklineC4 Therapeutics price target raised to $50 from $39 at Brookline

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$10

Buy

274.53%

Upside

Assigned

12/09/24

Terence Flynn

Morgan Stanley

―

Hold

―

Reiterated

12/09/24

C4 Therapeutics (CCCC) Gets a Hold from Morgan Stanley

Sudan Loganathan

Stephens

Hold

49.81%

Upside

Initiated

11/18/24

C4 Therapeutics initiated with an Equal Weight at StephensC4 Therapeutics initiated with an Equal Weight at Stephens

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$10

Buy

274.53%

Upside

Assigned

11/08/24

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$9→$10

Buy

274.53%

Upside

Reiterated

09/16/24

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Bradley Canino

Guggenheim

Buy

199.63%

Upside

Initiated

09/03/25

C4 Therapeutics initiated with a Buy at GuggenheimC4 Therapeutics initiated with a Buy at Guggenheim

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

Buy

162.17%

Upside

Reiterated

08/11/25

Evercore ISI Sticks to Their Buy Rating for C4 Therapeutics (CCCC)Earnings Overload SMID Biotech Week in Review

Unknown Analyst

UBS

Not Ranked

UBS

$4→$3.5

Hold

31.09%

Upside

Reiterated

03/03/25

C4 Therapeutics (CCCC) PT Lowered to $3.50 at UBSUBS analyst Colin Bristow lowered the price target on C4 Therapeutics (NASDAQ: CCCC) to $3.50 (from $4.00) while maintaining a Neutral rating.

Etzer Darout

BMO Capital

$20

Buy

649.06%

Upside

Reiterated

02/27/25

C4 Therapeutics: Promising Clinical Developments and Strategic Plans Justify Buy Rating

Derek Archila

Wells Fargo

$12

Buy

349.44%

Upside

Reiterated

02/27/25

Leah R. Cann

Brookline Capital Markets

$39→$50

Buy

1772.66%

Upside

Reiterated

01/06/25

C4 Therapeutics price target raised to $50 from $39 at BrooklineC4 Therapeutics price target raised to $50 from $39 at Brookline

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$10

Buy

274.53%

Upside

Assigned

12/09/24

Terence Flynn

Morgan Stanley

―

Hold

―

Reiterated

12/09/24

C4 Therapeutics (CCCC) Gets a Hold from Morgan Stanley

Sudan Loganathan

Stephens

Hold

49.81%

Upside

Initiated

11/18/24

C4 Therapeutics initiated with an Equal Weight at StephensC4 Therapeutics initiated with an Equal Weight at Stephens

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$10

Buy

274.53%

Upside

Assigned

11/08/24

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$9→$10

Buy

274.53%

Upside

Reiterated

09/16/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering C4 Therapeutics

1 Month

xxx

Success Rate

4/11 ratings generated profit

Average Return

-3.69%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 36.36% of your transactions generating a profit, with an average return of -3.69% per trade.

3 Months

xxx

Success Rate

6/17 ratings generated profit

Average Return

+20.26%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 35.29% of your transactions generating a profit, with an average return of +20.26% per trade.

1 Year

Etzer DaroutBMO Capital

Success Rate

4/17 ratings generated profit

Average Return

-13.18%

reiterated a buy rating 6 months ago

Copying Etzer Darout's trades and holding each position for 1 Year would result in 23.53% of your transactions generating a profit, with an average return of -13.18% per trade.

2 Years

xxx

Success Rate

2/17 ratings generated profit

Average Return

-32.81%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 11.76% of your transactions generating a profit, with an average return of -32.81% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CCCC Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CCCC has received 2 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. CCCC average Analyst price target in the past 3 months is 7.50.

Each month's total comprises the sum of three months' worth of ratings.

CCCC Financial Forecast

CCCC Earnings Forecast

Next quarter’s earnings estimate for CCCC is -$0.40 with a range of -$0.47 to -$0.32. The previous quarter’s EPS was -$0.37. CCCC beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.17% of the time in the same period. In the last calendar year CCCC has Outperformed its overall industry.

CCCC Sales Forecast

Next quarter’s sales forecast for CCCC is $6.28M with a range of $5.00M to $8.00M. The previous quarter’s sales results were $6.46M. CCCC beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.22% of the time in the same period. In the last calendar year CCCC has Outperformed its overall industry.

CCCC Stock Forecast FAQ

What is CCCC’s average 12-month price target, according to analysts?

Based on analyst ratings, C4 Therapeutics’s 12-month average price target is 7.50.

What is CCCC’s upside potential, based on the analysts’ average price target?

C4 Therapeutics has 180.90% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CCCC a Buy, Sell or Hold?

C4 Therapeutics has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.

What is C4 Therapeutics’s price target?

The average price target for C4 Therapeutics is 7.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $8.00 ,the lowest forecast is $7.00. The average price target represents 180.90% Increase from the current price of $2.67.

What do analysts say about C4 Therapeutics?

C4 Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of CCCC?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

C4 Therapeutics (CCCC) Stock Forecast & Price Target

CCCC Analyst Ratings

CCCC Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering C4 Therapeutics

CCCC Analyst Recommendation Trends

CCCC Financial Forecast

CCCC Earnings Forecast

CCCC Sales Forecast

CCCC Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts